MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.61 -0.60%

-$0.09 today

Market cap
$175.71M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.17M

Average 0.09M

MDWD Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

MediWound Ltd.NASDAQ: MDWD

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $378K rose 5.6% year over year, behind the +27.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 45.2% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.

Context

  • Depreciation & amortization amounted to 10.1% of revenue in FY2025, up 2.7 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.6% toward the trailing-twelve-month pace of +27.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$378K-45.2% QoQ
Last fiscal yearDec 2025
$1.71M+15.3% YoY
LTMMar 2026
$1.88M+27.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.6%——
1 year+15.3%——
3-year CAGR+10.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
1.71M USD
Year-over-year change
+15.3%
4-year CAGR
+8.4%

Depreciation & Amortization vs competitors

How MDWD compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +27.6% is the 2nd highest of 9, against a peer median of -16.3%.
  • Depreciation & amortization amounts to 13.0% of revenue for MDWD, versus a peer median of 37.6%.
MDWD Competitors
Depreciation & Amortization for MDWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€3.22M EUR-38.0%+23.8%71.9%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$2.42M USD+13.1%+32.0%136.2%
IVVDInvivyd, Inc.LTM Mar 2026$1.88M USD-43.4%+65.8%3.4%
MDWDMediWound Ltd.LTM Mar 2026$1.88M USD+27.6%+10.4%13.0%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$718K USD-3878.9%——
TARAProtara Therapeutics, Inc.LTM Mar 2026$369K USD+11.1%+13.4%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$334K USD+5.4%+13.8%1.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$263.36K USD+65.0%+17.8%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$152K USD-97.9%——
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$142.16K USD———
Peer median (excluding MDWD) —-16.3%+20.8%37.6%

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Depreciation & Amortization1.24M1.27M1.3M1.48M1.71M
Deferred Income Tax(124K)0000
Stock-Based Compensation1.67M1.95M1.94M3.14M3.11M
Change in Working Capital162K(7.24M)2.34M1.27M4.77M
Accounts Receivables929K(7.58M)4.76M(1.02M)4.88M
Inventory257K(721K)(906K)187K(1.36M)
Accounts Payables1.72M414K(594K)406K2.35M
Other Working Capital(2.75M)645K(928K)1.7M(1.1M)
Other Non-Cash Items1.69M11.74M(9.33M)10.71M(236K)
Operating Cash Flow(8.92M)(11.89M)(10.47M)(13.62M)(14.53M)
Capital Expenditures(489K)(555K)(6.46M)(6.27M)(5.51M)
Acquisitions (Net)00000
Purchases of Investments0000(14.04M)
Sales of Investments4M0000
Other Investing Activities35K74K(27.86M)(2.12M)0
Investing Cash Flow3.55M(481K)(34.32M)(8.4M)(19.54M)
Debt Repayment000(928K)0
Common Stock Issued3K38.38M24.91M22.17M31.05M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.05M)(2.62M)(1.99M)(1.84M)(1.43M)
Financing Cash Flow(1.05M)35.76M22.92M19.39M29.62M
Effect of Forex Changes88K(549K)(160K)(84K)95K
Net Change in Cash(6.33M)22.85M(22.03M)(2.71M)(4.36M)
Free Cash Flow(9.41M)(12.44M)(16.93M)(19.9M)(20.04M)

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.